Table 3.
Reliable change index for primary outcome measure (S-DAI score).
| Participant number | Randomization allocation | x1 | x2 | x2 – x1 | sx | rt | SEM | st | SEdiff | RCI | Sig. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 708 | propranolol | 24 | 33 | 9 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | 2.9631 | Sig. |
| 786 | propranolol | 27 | 27 | 0 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | 0.0000 | N/S |
| 860 | propranolol | 35 | 28 | −7 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −2.3046 | Sig. |
| 942 | propranolol | 30 | 23 | −7 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −2.3046 | Sig. |
| 945 | propranolol | 41 | 43 | 2 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | 0.6585 | N/S |
| 947 | propranolol | 34 | 28 | −6 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −1.9754 | Sig. |
| 949 | propranolol | 28 | 28 | 0 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | 0.0000 | N/S |
| 950 | propranolol | 29 | 15 | −14 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −4.6093 | Sig. |
| 953 | propranolol | 33 | 20 | −13 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −4.2800 | Sig. |
| 954 | propranolol | 38 | 39 | 1 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | 0.3292 | N/S |
| 957 | propranolol | 33 | 20 | −13 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −4,2800 | Sig. |
| 959 | propranolol | 45 | 45 | 0 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | 0.0000 | N/S |
| 961 | propranolol | 40 | 38 | −2 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −0.6585 | N/S |
| 965 | propranolol | 41 | 41 | 0 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | 0.0000 | N/S |
| 970 | propranolol | 16 | 18 | 2 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | 0.6585 | N/S |
| 972 | propranolol | 22 | 27 | 5 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | 1.6462 | N/S |
| 975 | propranolol | 33 | 26 | −7 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −2.3046 | Sig. |
| 979 | propranolol | 34 | 32 | −2 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −0.6585 | N/S |
| 982 | propranolol | 27 | 21 | −6 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −1.9754 | Sig. |
| 702 | placebo | 39 | 27 | −12 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −3.9508 | Sig. |
| 709 | placebo | 32 | 23 | −9 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −2.9631 | Sig. |
| 859 | placebo | 42 | 27 | −15 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −4.9385 | Sig. |
| 943 | placebo | 27 | 35 | 8 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | 2.6339 | Sig. |
| 944 | placebo | 43 | 43 | 0 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | 0.0000 | N/S |
| 948 | placebo | 20 | 26 | 6 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | 1.9754 | Sig. |
| 952 | placebo | 26 | 17 | −9 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −2.9631 | Sig. |
| 955 | placebo | 29 | 26 | −3 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −0.9877 | N/S |
| 956 | placebo | 30 | 30 | 0 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | 0.0000 | N/S |
| 958 | placebo | 22 | 19 | −3 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −0.9877 | N/S |
| 960 | placebo | 31 | 25 | −6 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −1.9754 | Sig. |
| 964 | placebo | 38 | 36 | −2 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −0.6585 | N/S |
| 966 | placebo | 35 | 29 | −6 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −1.9754 | Sig. |
| 968 | placebo | 19 | 18 | −1 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −0.3292 | N/S |
| 973 | placebo | 28 | 25 | −3 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −0.9877 | N/S |
| 976 | placebo | 41 | 27 | −14 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −4.6093 | Sig. |
| 980 | placebo | 35 | 28 | −7 | 7.535 | 0.88 | 2.610 | 6.2 | 3.037 | −2.3046 | Sig. |
N/S, Not statistically significant (-1.96 > RCI < 1.96); RCI, Reliable Change Index = (x1 – x2) / Sdiff; rt, Reliability of the test (Cronbach's α); S-DAI, Short version of the Dental Anxiety Inventory with total test scores ranging from 9 to 45 (Aartman, 1998); SEdiff, Standard Error of measurement of the difference = √ (2 · (SEM)2); SEM, Standard Error of the Mean = SX · √ (1 –rt); Sig., Statistically significant (R > 1.96 or RCI < −1.96); st, Standard deviation of the test; sX, Standard deviation of test takers' scores = (sx2 + sx1) / 2; x1, Baseline score; x2, Follow-up score; x2 – x1, Observed difference in score.